Lookup NU author(s): Harriet Southgate,
Dr Lindi Chen,
Professor Nicola Curtin,
Professor Deborah Tweddle
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© Copyright © 2020 Southgate, Chen, Curtin and Tweddle.Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB) remains <50%. Most cases initially respond to treatment but almost half will subsequently relapse with aggressive treatment resistant disease. Novel treatments exploiting the molecular pathology of NB and/or overcoming resistance to current genotoxic therapies are needed before survival rates can significantly improve. DNA damage response (DDR) defects are frequently observed in HR-NB including allelic deletion and loss of function mutations in key DDR genes, oncogene induced replication stress and cell cycle checkpoint dysfunction. Exploiting defects in the DDR has been a successful treatment strategy in some adult cancers. Here we review the genetic features of HR-NB which lead to DDR defects and the emerging molecular targeting agents to exploit them.
Author(s): Southgate HED, Chen L, Curtin NJ, Tweddle DA
Publication type: Review
Publication status: Published
Journal: Frontiers in Oncology
Online publication date: 03/04/2020
Acceptance date: 03/03/2020
ISSN (electronic): 2234-943X
Publisher: Frontiers Media S.A.